Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)
Conditions: Breast Cancer; Renal Cell Carcinoma Interventions: Drug: IPI-549; Drug: Atezolizumab; Drug: nab-paclitaxel; Drug: Bevacizumab Sponsors: Infinity Pharmaceuticals, Inc.; Roche Pharma AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Research